In addition, although no drug candidates targeting Pin1 for neuronal diseases have been reported, specific antibodies targeting Thr231 of tau, which is the Pin1 binding site, have been developed, and such monoclonal antibodies could effectively prevent tau-related pathology development in AD and TBI patients by entering neurons and blocking the induction of pathological cis p-tau (Shahpasand et al., 2018; Chen D. et al., 2020; Wang et al., 2020), which is closely related to cognitive impairment and dementia (Albayram et al., 2017; Qiu et al., 2021). The gene discussed is MAPT; the disease is Alzheimer disease.